Atossa Announces CVR Agreement for Rare Disease PRV Proceeds
Atossa Therapeutics announced a stapled CVR agreement entitling holders to 25% of net proceeds from a future rare disease PRV sale, up to $50 million. The filing underscores ongoing corporate strategy to unlock value from healthcare programs.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed